Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 TaiwanJ Inks $26M Deal with Newsoara | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

TaiwanJ Inks $26M Deal with Newsoara

For licensing and co-development contract with Newsoara on JKB-122 Asian rights

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

TaiwanJ Pharmaceuticals has signed a $26 million contract with Shanghai, China-based Newsoara Biopharma to license out its drug candidate JKB-122 for further development in Asia. JKB-122 is a phase 2 nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) drug candidate. Newsoara will be responsible for the clinical development and market commercialization of JKB-122 in Asia, except Taiwan.
 
According to the agreement, TaiwanJ will receive $2 million upfront and up to $24 million in milestone payments. The two companies are also working together to conduct preclinical research for JKB-122’s second generation compound JKB-133. In addition, TaiwanJ will maintain its right of global clinical development and subsequent worldwide market commercialization.
 
JKB-122 is a small molecule and a long-acting TLR4 antagonist showing anti-fibrotic, immuno-modulating, and anti-inflammatory effects for the treatments of chronic liver diseases including Non-Alcoholic Fatty Liver Disease (NAFLD), Autoimmune Hepatitis (AIH), and Non-Alcoholic Steatohepatitis (NASH).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics